Form 4: Relay Therapeutics CFO Sells Shares Under 10b5-1 Plan

Relay Therapeutics CFO Thomas Catinazzo reported the sale of 17,717 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Thomas Catinazzo, Chief Financial Officer of Relay Therapeutics, Inc., reported a transaction on July 6, 2026.
• The transaction involved the sale of 17,717 shares of common stock.
• This sale was executed as part of a Rule 10b5-1 trading plan adopted on October 30, 2025.
• The weighted average sale price for these shares was $18.69, with individual trades ranging from $18.39 to $19.38.
• Following this transaction, Catinazzo beneficially owns 159,744 shares of common stock.
• The filing also notes that 9,807 of the owned shares are underlying restricted stock units.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the sale of shares by a key executive, despite the transaction being conducted under a pre-arranged plan.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating pre-planned and potentially non-insider trading related activity.
• The reporting person retains a significant number of shares (159,744) after the sale.

Negatives

• A significant number of shares were sold by a key executive, which could be perceived negatively by the market.
• The sale represents a reduction in the CFO's direct beneficial ownership.

Risks

• The sale of shares by a Chief Financial Officer, even under a 10b5-1 plan, can sometimes be interpreted by the market as a lack of confidence in future stock performance.
• The weighted average sale price of $18.69 might be lower than the purchase price or current market price, though this is not explicitly stated.

Future Outlook

The filing itself does not contain forward-looking statements or guidance regarding the company's future performance. It solely reports a past transaction.

Management Comments

• The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.
• The price reported reflects the weighted average sale price, and the reporting person undertakes to provide full information regarding the number of shares sold at each respective price upon request.

Industry Context

StockSavvy.ai notes that Form 4 filings, particularly those involving Rule 10b5-1 plans, are common for executives in the biotechnology and pharmaceutical sectors. These plans allow for predetermined stock sales, mitigating concerns about insider trading, but significant sales can still influence market perception.

Stakeholder Impact

• Shareholders: May view the sale by the CFO with caution, although the Rule 10b5-1 plan mitigates insider trading concerns. The retained ownership level is substantial.
• Employees: Similar to shareholders, the sale might raise questions, but the plan's existence provides context.
• Creditors/Suppliers: Unlikely to be directly impacted by this specific transaction.

Next Steps

• The reporting person may be required to provide further details on individual sale prices upon request from the SEC, the Issuer, or a security holder.

Key Dates

Recommendation

The filing reports a stock sale by the CFO under a Rule 10b5-1 plan. While such sales can sometimes signal a lack of confidence, the pre-planned nature and the significant remaining beneficial ownership suggest it's a routine financial management activity rather than a strong indicator of negative future performance. Therefore, a 'hold' recommendation is appropriate, pending further company-specific developments.

Keywords

Form 4, SEC Filing, Insider Trading, Rule 10b5-1, Stock Sale, Relay Therapeutics, RLAY, Thomas Catinazzo, Chief Financial Officer, Beneficial Ownership